Zebra Technologies Sees Q1 Adj. EPS Below Market; Raises Annualized Organic Net Sales Growth View

While announcing weak profit and higher net sales in its fourth quarter, Zebra Technologies Corp. (ZBRA) issued outlook for first quarter and fiscal 2022, and raised long-term view.

For the first quarter, the company expects adjusted earnings per share are expected to be in the range of $3.70 to $4.00.

On average, nine analysts polled by Thomson Reuters expect earnings of $4.4 per share for the quarter. Analysts' estimates typically exclude special items.

Adjusted net sales are expected to increase 1 percent to 3 percent from last year, and adjusted EBITDA margin to be approximately 20 percent.

For fiscal 2022, the company expects adjusted net sales to increase 3 percent to 7 percent from 2021, and adjusted EBITDA margin to be between 23 percent and 24 percent. Free cash flow is expected to be at least $900 million.

Further, for the long-term, the company raised its annualized organic net sales growth outlook to 5 percent to 7 percent, from 4 percent to 5 percent expected earlier.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route. Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie. Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.
Follow RTT